NEW DELHI – India's drug quality administration is cracking down on companies that manufacture and sell unauthorized and untested fixed-dose combination (FDC) drugs, following recent inspections that brought that issue into the spotlight. Read More
Fimecs Inc., of Kanagawa, Japan, raised ¥250 million (US$2.3 million) in funding by third-party allocation of shares underwritten by Tokyo-based Cosmo Bio Co. Ltd. and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan. The company plans to use the proceeds to fund research and development of its protein degradation therapeutics for the treatment of cancer. In other news, Fimecs licensed immuno-oncology compounds, including E3 ligase binders and pseudokinase targeting binders, from Takeda Pharmaceutical. Read More
HONG KONG – The Central Drugs Standard Control Organization (CDSCO) of India is setting up a national database, known as Sugam, of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues. Read More
In findings that could improve both risk prediction and treatment of anaphylactic shock, researchers at the Institute Pasteur have discovered that IgG antibodies could activate platelets, exacerbating the severity of anaphylactic episodes. Read More
PERTH, Australia – Another battle is brewing over Australia's Research and Development Tax Incentive in the lead up to the annual Federal Budget that is released in early May. Read More
Despite the fact that the industry inked more than 1,000 deals last year, it appears that biopharma companies are not losing their appetite for dealmaking. According to data from BioWorld and Cortellis Deals Intelligence, there were 271 deals signed in the first quarter of 2018, on par with 2017 first quarter transactions. Read More
